ST elevation myocardial infarction: Difference between revisions
| Line 46: | Line 46: | ||
[[ST elevation myocardial infarction coronary artery bypass grafting|CABG]] | [[ST elevation myocardial infarction management of patients who were not reperfused|Management of Patients Who Were Not Reperfused]] | [[ST elevation myocardial infarction assessing success of reperfusion|Assessing Success of Reperfusion]] | [[ST elevation myocardial infarction coronary artery bypass grafting|CABG]] | [[ST elevation myocardial infarction management of patients who were not reperfused|Management of Patients Who Were Not Reperfused]] | [[ST elevation myocardial infarction assessing success of reperfusion|Assessing Success of Reperfusion]] | ||
'''Antithrombin Therapy''' | '''Antithrombin Therapy''' | [[ST elevation myocardial infarction anticoagulant and antithrombotic therapy|Antithrombin therapy]] | [[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Unfractionated Heparin|Unfractionated heparin]] | [[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Enoxaparin|Low Molecular Weight Heparinoid Therapy]] | [[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Bivalirudin|Direct Thrombin Inhibitor Therapy]] | [[ST elevation myocardial infarction anticoagulant and antithrombotic therapy#Fondaparinux|Factor Xa Inhibition]] | [[ST elevation myocardial infarction deep vein thrombosis prophylaxis and anticoagulation|DVT prophylaxis]] | [[ST elevation myocardial infarction deep vein thrombosis prophylaxis and anticoagulation|Long term anticoagulation]] | ||
'''Antiplatelet Agents''' | [[ST elevation myocardial infarction aspirin therapy|Aspirin]] | [[ST elevation myocardial infarction thienopyridine therapy|Thienopyridine Therapy]] | [[ST elevation myocardial infarction glycoprotein IIbIIIa inhibition|Glycoprotein IIbIIIa Inhibition]] | '''Antiplatelet Agents''' | [[ST elevation myocardial infarction aspirin therapy|Aspirin]] | [[ST elevation myocardial infarction thienopyridine therapy|Thienopyridine Therapy]] | [[ST elevation myocardial infarction glycoprotein IIbIIIa inhibition|Glycoprotein IIbIIIa Inhibition]] | ||
Revision as of 16:46, 31 January 2013
|
ST Elevation Myocardial Infarction Microchapters |
|
Differentiating ST elevation myocardial infarction from other Diseases |
|
Diagnosis |
|
Treatment |
|
|
Case Studies |
|
ST elevation myocardial infarction On the Web |
|
Directions to Hospitals Treating ST elevation myocardial infarction |
|
Risk calculators and risk factors for ST elevation myocardial infarction |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Anne-Marie Anagnostopoulos, M.D.; Debanik Chaudhuri, M.D.; Robert Salazar, M.D.
Synonyms and keywords: AMI, STEMI, heart attack, MI, myocardial infarct, acute MI, coronary, coronary thrombosis
Overview
Pathophysiology
Pathophysiology of Vessel Occlusion | Pathophysiology of Reperfusion | Gross Pathology | Histopathology
Causes
Differentiating ST elevation myocardial infarction from other Diseases
Epidemiology and Demographics
Risk Factors
Risk Stratification
Triggers
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Chest X Ray | Cardiac MRI | Echocardiography | Coronary Angiography
Treatment
Pre-Hospital Care
Initial Care
Oxygen | Nitrates | Analgesics | Aspirin | Beta Blockers | Antithrombins | The coronary care unit | The step down unit | STEMI and Out-of-Hospital Cardiac Arrest
Pharmacologic Reperfusion | Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI) | Fibrinolysis
Mechanical Reperfusion | The importance of reducing Door-to-Balloon times | Primary PCI | Adjunctive and Rescue PCI | Rescue PCI | Facilitated PCI | Adjunctive PCI | CABG | Management of Patients Who Were Not Reperfused | Assessing Success of Reperfusion
Antithrombin Therapy | Antithrombin therapy | Unfractionated heparin | Low Molecular Weight Heparinoid Therapy | Direct Thrombin Inhibitor Therapy | Factor Xa Inhibition | DVT prophylaxis | Long term anticoagulation
Antiplatelet Agents | Aspirin | Thienopyridine Therapy | Glycoprotein IIbIIIa Inhibition
Other Initial Therapy | Inhibition of the Renin-Angiotensin-Aldosterone System | Magnesium Therapy | Glucose Control | Calcium Channel Blocker Therapy | Lipid Management
Pre-Discharge Care
Long-Term Medical Therapy and Secondary Prevention
Overview | Inhibition of the Renin-Angiotensin-Aldosterone System | Cardiac Rehabilitation | Pacemaker Implantation | Long Term Anticoagulation
Case Studies
Case #1 | Case #2 | Case #3 | Case #4 | Case #5
Related Chapters
- Acute coronary syndrome
- Angina
- Cardiac arrest
- Coronary thrombosis
- Hibernating myocardium
- Stunned myocardium
- Ventricular remodeling
- The Living Guidelines: STEMI
- In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme used by the ACC / AHA guidelines. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.
External Links
- Clinical Trial Results: An up to date resource of Cardiovascular Research
- Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack - based on information of the Framingham Heart Study, from the United States National Heart, Lung and Blood Institute
- Heart Attack - overview of resources from MedlinePlus.
- American College of Cardiology (ACC) Door to Balloon (D2B) Initiative.
- American Heart Association's Heart Attack web site - Information and resources for preventing, recognizing and treating heart attack.
Disclaimer
Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here.